Trastuzumab (Herceptin®; Genentech Inc, South San Francisco, CA), a humanized IgG1 mAb directed against HER2, was initially approved in 1998 in the United States for the treatment of HER2-overexpressing breast cancer [11]. Here, ERBB2 is linked to breast carcinoma.